Imprint

Published By

Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim / Rhein, Germany

Trade Register of the Local Court of Mainz, HRB 21063
Identification number for turnover tax: DE 811 138 149

Management Board: Allan Hillgrove, Dr. Michel Pairet, Torsten Rieck

Contact

Phone: +49-6132-77-0
Fax: +49-6132-72-0
E-Mail: For queries please click here or write to press@boehringer-ingelheim.com


Report an adverse event

If you wish to report an adverse event (AE) after treatment with one of our products, please select your country on the following page. This will allow reporting of AEs in line with the reporting procedure effective in your country for reporting.

Boehringer Ingelheim local websites

Back to top

This site uses cookies to improve your browsing experience. By using this site, you agree to their use.

Cookie policy
I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international product information intended for Healthcare Professionals about afatinib for non-small-cell lung cancer treatment.

I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information about afatinib for non-small-cell lung cancer treatment.

Country-specific product information

Country-specific product information

Click here for country-specific product information intended for Healthcare Professionals about afatinib for non-small-cell lung cancer treatment.